544 related articles for article (PubMed ID: 24378877)
1. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
2. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
Petrillo M; Zucchetti M; Cianci S; Morosi L; Ronsini C; Colombo A; D'Incalci M; Scambia G; Fagotti A
J Gynecol Oncol; 2019 Jul; 30(4):e59. PubMed ID: 31074245
[TBL] [Abstract][Full Text] [Related]
4. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence.
Cianci S; Ronsini C; Vizzielli G; Tropea A; Biondi A; Scambia G; Fagotti A
Updates Surg; 2019 Jun; 71(2):389-394. PubMed ID: 30406932
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
Carrabin N; Mithieux F; Meeus P; Trédan O; Guastalla JP; Bachelot T; Labidi SI; Treilleux I; Rivoire M; Ray-Coquard I
Bull Cancer; 2010 Apr; 97(4):E23-32. PubMed ID: 20202920
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.
Frenel JS; Leux C; Pouplin L; Ferron G; Berton Rigaud D; Bourbouloux E; Dravet F; Jaffre I; Classe JM
J Surg Oncol; 2011 Jan; 103(1):10-6. PubMed ID: 21031424
[TBL] [Abstract][Full Text] [Related]
12. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Chiva LM; Gonzalez-Martin A
Gynecol Oncol; 2015 Jan; 136(1):130-5. PubMed ID: 25434634
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
15. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
[TBL] [Abstract][Full Text] [Related]
18. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
[TBL] [Abstract][Full Text] [Related]
19. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
20. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
